This article is more than 5 years old. Information may no longer be current.
Roche announces phase 3 trials for lampalizumab
Click Here to Manage Email Alerts
Roche/Genentech announced the initiation of two phase 3 clinical studies for lampalizumab, an investigational drug for the treatment of geographic atrophy, at the Euretina Congress in London.
The phase 3 studies are aimed to determine lampalizumab’s safety and efficacy, as well as its potential to slow the progression of geographic atrophy (GA). Researchers will also investigate whether patients with the complement factor I biomarker will benefit from the drug, according to a company press release.
“Lampalizumab has the potential to represent a significant breakthrough for this disease and could provide real hope for GA patients,” Sandra Horning, MD, head of global product development and chief medical officer at Roche, said in the release. “It is the first complement-targeted therapy for GA to enter phase 3 and the only ophthalmic drug in clinical development that specifically targets complement factor D.”